Rab27A Antibody [P23F7]

Katalog-Nr. F4892

Drucken

Biologische Beschreibung

Spezifität Rab27A Antibody [P23F7] weist endogene Spiegel des gesamten Rab27A-Proteins nach.
Hintergrund Rab27A, eine kleine GTPase der Rab-Familie innerhalb der Ras-Superfamilie, lokalisiert in sekretorischen Lysosomen wie Melanosomen in Melanozyten und lytischen Granula in zytotoxischen T-Lymphozyten und reguliert die Exozytose im Spätstadium durch GTP/GDP-Zyklus. Sie weist eine kanonische globuläre Faltung von sechs β-Strängen und fünf α-Helices mit Switch-I- (Reste 35–45) und Switch-II-Regionen (67–79) auf, die bei GTP-Bindung Konformationsänderungen erfahren, um Effektor-Bindungsoberflächen einschließlich Gln78 und Tyr69 für spezifische Interaktionen freizulegen, sowie ein hypervariables C-terminales Prenylierungsmotiv (CCXL) mit Farnesyl- oder Geranylgeranyl-Lipiden zur Membranverankerung und ein RabSF-Motiv, das den GDP-Zustand stabilisiert. In ihrer GTP-gebundenen aktiven Form rekrutiert Rab27A über diese Switch-Regionen verschiedene Effektoren wie Slac2c/MyRIP, Exophilin4/Slp2-a und Munc13-4, um Vesikel an Aktin-/Myosin-Motoren zu binden (Myosin-Va zur peripheren Melanosom-Einfangung) oder das Priming/Docking an der Plasmamembran für die SNARE-vermittelte Fusion bei der zytotoxischen Granula-Exozytose, der Insulinsekretion aus pankreatischen β-Zellen durch Modulation der CaV1.3-Kanal-Spannungsabhängigkeit über die II-III-Linker-Bindung zur Verbesserung des Ca2+-Einstroms und der VEGF-A-Freisetzung im retinalen Pigmentepithel sowie die Exosomen-Biogenese/-Sekretion von MMPs, Chemokinen und miRNAs zu fördern, um die Invasion/Metastasierung von Krebszellen bei Melanom-, Lungen- und Brusttumoren voranzutreiben. Mutationen wie G40R beim Griscelli-Syndrom Typ 2 beeinträchtigen die Effektorbindung und GTP-Hydrolyse, stören die Degranulation zytotoxischer T-/NK-Zellen, die Freisetzung von Thrombozytengranula und den Melanosom-Transport, was zu partiellem Albinismus und primärer Immunschwäche führt, während ihre Hochregulierung mit einer schlechten Prognose bei Krebserkrankungen durch PI3K/Akt- und ERK-Signalweg-Amplifikation über Exosomen-vermittelte parakrine Signalgebung korreliert.

Nutzungsinformationen

Anwendung WB, IHC Verdünnung
WB IHC
1:800 1:650
Reaktivität Human, Mouse, Rat
Quelle Mouse Monoclonal Antibody MW 25 kDa,41 kDa
Lagerpuffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Lagerung
(Ab dem Datum des Erhalts)
-20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature.
2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 120 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:400), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
IHC
Experimental Protocol:
 
Deparaffinization/Rehydration
1. Deparaffinize/hydrate sections:
2. Incubate sections in three washes of xylene for 5 min each.
3. Incubate sections in two washes of 100% ethanol for 10 min each.
4. Incubate sections in two washes of 95% ethanol for 10 min each.
5. Wash sections two times in dH2O for 5 min each.
6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
 
Staining
1. Wash sections in dH2O three times for 5 min each.
2. Incubate sections in 3% hydrogen peroxide for 10 min.
3. Wash sections in dH2O two times for 5 min each.
4. Wash sections in wash buffer for 5 min.
5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
9. Wash sections three times with wash buffer for 5 min each.
10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
12. Immerse slides in dH2O.
13. If desired, counterstain sections with hematoxylin.
14. Wash sections in dH2O two times for 5 min each.
15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
16. Mount sections with coverslips and mounting medium.
 

Referenzen

  • https://pubmed.ncbi.nlm.nih.gov/18940603/
  • https://pubmed.ncbi.nlm.nih.gov/28632484/

Anwendungsdaten

WB

Validiert von Selleck

  • F4892-wb
    Lane 1: HL60, Lane 2: HL60 (KO RAB27A), Lane 3: Jurkat, Lane 4: MCF7